Repligen, a maker of tools used to manufacture biologic drugs, is acquiring BioLife Solutions for $1.5 billion — a move to own more of the supply chain behind cell and gene therapies.
Announced in mid-August 2026, the deal adds BioLife’s biopreservation technology — notably its CryoStor products, used to keep living cells viable through freezing and storage — to Repligen’s existing bioprocessing portfolio. Cell and gene therapies depend on keeping fragile cells alive from manufacturing to the patient, making cold-chain and preservation tools a critical, often overlooked, link.
The strategy
Analysts frame the acquisition as part of pharma’s broader shift toward integrated cell- and gene-therapy supply chains — companies bringing more of the manufacturing stack in-house rather than stitching together many suppliers. The cell and gene therapy market has matured significantly in recent years as bioprocessing technology has advanced, raising the value of owning key steps end to end.
Why it matters
Cell and gene therapies are among medicine’s most promising — and most complex to manufacture and deliver. Consolidation among the “picks and shovels” suppliers, like Repligen buying BioLife, reflects an industry trying to make these therapies more reliable and scalable. For Repligen, it broadens what it can offer drugmakers as demand for these advanced treatments grows.